TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence (TRICIA)
Triple Negative Breast Cancer Markers in Liquid Biopsies Using Artificial Intelligence (TRICIA Study)
Sponsor: Exactis Innovation
This observational or N/A phase trial investigates Breast Cancer and is currently actively recruiting participants. Exactis Innovation leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Dec 2025 — Present [monthly]
Recruiting
Status: Unknown → Recruiting
-
Sep 2024 — Dec 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jul 2023 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Dec 2021 — Jul 2023 [monthly]
Recruiting
▶ Show 1 earlier version
-
Jun 2021 — Dec 2021 [monthly]
Recruiting
First recorded
Dec 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Exactis Innovation
- Jewish General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .